Crocetin’s ability to restore oxidative phosphorylation (OXPHOS) and extend lifespan in aged mice may stem from a transient, dose‑dependent inhibition of prolyl hydroxylase domain proteins (PHDs), leading to HIF‑1α stabilization and a hormetic activation of mitochondrial biogenesis pathways. At the low hippocampal concentration achieved after intravenous administration (~31 nM) 3, crocetin’s dicarboxylic acid structure can chelate the ferrous iron required in the PHD2 catalytic pocket, mimicking the action of known iron‑chelating HIF stabilizers. This brief HIF‑1α rise would increase transcription of hypoxia‑responsive genes such as BNIP3 and NIX, promoting mitophagy of damaged mitochondria, while simultaneously upregulating PGC‑1α via HIF‑1α‑dependent co‑activator recruitment, thereby boosting OXPHOS gene expression to youthful levels as observed in four‑month treatment studies 4. Chronic exposure, however, triggers compensatory upregulation of P-glycoprotein (P‑gp) and accelerated crocetin efflux, limiting brain accumulation and preventing sustained HIF‑1α activation—a feedback loop that explains the observed P‑gp induction at 25‑50 µM crocetin 3 and the need for intermittent dosing to maintain efficacy.

This hypothesis generates several falsifiable predictions: (1) Pharmacological PHD2 inhibition (e.g., with dimethyloxalylglycine) should reproduce crocetin’s OXPHOS gene upregulation and ATP increase in aged mouse brain tissue, whereas PHD2 over‑expression will blunt these effects. (2) Neuron‑specific HIF‑1α knockout mice treated with crocetin will fail to show the restoration of NAD+ levels, ATP production, or lifespan extension seen in wild‑type controls. (3) Germ‑free or antibiotic‑treated mice deficient in the gut microbiota enzymes that convert crocin to crocetin will exhibit attenuated HIF‑1α signaling and reduced neuroprotection despite identical crocin dosing, linking microbiome variability to the HIF‑1α axis. (4) Safranal, which operates via the kynurenine pathway, will not alter HIF‑1α stabilization, confirming pathway specificity.

Experimental validation could involve western blot quantification of HIF‑1α and its target genes in microdissected hippocampus after acute crocetin exposure, Seahorse assays to measure OXPHOS capacity, and metabolomic profiling of NAD+/NADH ratios. Longitudinal cohorts would assess whether intermittent crocetin regimens avoid P‑gp upregulation while preserving HIF‑1α‑mediated mitophagy signals. If supported, this model reframes crocetin not merely as an antioxidant but as a low‑dose HIF‑1α modulator that initiates a hormetic cascade to rejuvenate mitochondrial function in aging brains.